Clinical Trials Logo

Thrombotic Microangiopathies clinical trials

View clinical trials related to Thrombotic Microangiopathies.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04743804 Terminated - Clinical trials for Thrombotic Microangiopathy

Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger

Start date: July 1, 2021
Phase: Phase 3
Study type: Interventional

This study will investigate the efficacy and safety of ravulizumab compared to placebo in adult participants with thrombotic microangiopathy (TMA) associated with a trigger. Participants will be randomized to receive either ravulizumab plus best supportive care or placebo plus best supportive care. The treatment period is 26 weeks followed by a 26-week off-treatment follow-up period.

NCT ID: NCT00726544 Terminated - Clinical trials for Thrombotic Thrombocytopenic Purpura

Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The purpose of this ascending-dose research study is to determine whether the administration of ARC1779 Injection improves subject's health profile by protecting the brain, heart, and kidney from damage due to formation of small blood clots in blood vessels. It will also determine the safety of ARC1779 Injection, how ARC1779 Injection enters and leaves the blood and tissue over time, and its effect on laboratory tests related to blood clotting, heart and brain function, and other body systems.

NCT ID: NCT00593229 Terminated - Clinical trials for Thrombotic Thrombocytopenic Purpura

International Registry and Biorepository for TMA(Thrombotic Microangiopathy)

Start date: January 2007
Phase: N/A
Study type: Observational

This registry will collect clinical data and store biosamples (seru, plasma, urine, and DNA) annually from pediatric patients with thrombotic mcroangiopathy